SCHEMBL35115

SCHEMBL35115

C1CCCC2CC[C]2CC1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.33
NISCH Q9Y2I1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7391293 1.00 KMT2A (0.33) KMT2ANISCH
SCHEMBL295795 1.00
SCHEMBL70819 0.97
SCHEMBL542776 0.94 KMT2A (0.36) KMT2ANISCH
SCHEMBL9956415 0.94 KMT2A (0.36) KMT2ANISCH
SCHEMBL25327994 0.94 KMT2A (0.36) KMT2ANISCH
SCHEMBL13858690 0.94 KMT2A (0.36) KMT2ANISCH
SCHEMBL11594630 0.94 KMT2A (0.36) KMT2ANISCH
SCHEMBL7737845 0.94 KMT2A (0.36) KMT2ANISCH
SCHEMBL7992221 0.94 KMT2A (0.36) KMT2ANISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043601-B2 N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2024-07-23 US disclosed
WO-2024152000-A1 DISRUPTABLE LINKER COMPOSITIONS, SWITCHABLE BISPECIFIC T CELL NANOENGAGER (SWITCH-BITE) COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-07-18 WO disclosed
US-12037328-B2 Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 PRAMANA PHARMACEUTICALS INC. (CA) 2024-07-16 US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-12029731-B2 Acyl benzo[d]thiazol-2-amine and their methods of use BIOHAVEN THERAPEUTICS LTD. (US) 2024-07-09 US disclosed
US-20240216346-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same THE WISTAR INST (US) 2024-07-04 US disclosed
WO-2024134466-A1 SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-06-27 WO disclosed
US-12005046-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2024-06-11 US disclosed
US-12005047-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2024-06-11 US disclosed
US-11999723-B2 Pyrazole-containing macrophage migration inhibitory factor inhibitors YALE UNIVERSITY (US) 2024-06-04 US disclosed
US-20070197589-A1 Cyclic quaternary amino derivatives as modulators of chemokine receptors CELLTECH R&D LIMITED (GB) 2007-08-23 US disclosed
US-20060178350-A1 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes UNIVERSITEIT GENT (BE) 2006-08-10 US disclosed
WO-2006060884-A1 7-(2-CYCLOHEXYLIDENE-ETHYLIDENE)-SPIRO[4.5]DECANES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2006-06-15 WO disclosed
WO-2006060885-A1 7-(2-CYCLOHEXYLIDENE-ETHYLIDENE)-SPIRO[5.5]UNDECANES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2006-06-15 WO disclosed
EP-1620402-A1 CYCLIC QUATERNARY AMINO DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS Celltech R & D Limited (GB) 2006-02-01 EP disclosed
US-20050113414-A1 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens CELLTECH R&D LIMITED (GB) 2005-05-26 US disclosed
WO-2005003127-A1 BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF CXCR3 FUNCTION CELLTECH R & D LIMITED (GB) 2005-01-13 WO disclosed
EP-1478359-A1 PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Celltech R & D Limited (GB) 2004-11-24 EP disclosed
WO-2004094381-A1 CYCLIC QUATERNARY AMINO DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CELLTECH R & D LIMITED (GB) 2004-11-04 WO disclosed
WO-2003070242-A1 PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES CELLTECH R & D LIMITED (GB) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999723-B2 Pyrazole-containing macrophage migration inhibitory factor inhibitors MIF, MMP12, CSF1R KMT2A 2637/4885NISCH 2920/4885
US-20050113414-A1 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens CXCR3, ACKR3, CCR1 KMT2A 4542/4885NISCH 4383/4885
US-12005046-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 KMT2A 2213/4885NISCH 4640/4885
US-12043601-B2 N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same BAK1, NAAA, CASP3 KMT2A 299/4885NISCH 500/4885
US-12029731-B2 Acyl benzo[d]thiazol-2-amine and their methods of use BRCA1, ABAT, HDAC1 KMT2A 422/4885NISCH 1719/4885
US-12005047-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 KMT2A 2213/4885NISCH 4640/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 KMT2A 1444/4885NISCH 1555/4885
US-20060178350-A1 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes NR3C2, PKD2, REN KMT2A 3114/4885NISCH 315/4885
US-20070197589-A1 Cyclic quaternary amino derivatives as modulators of chemokine receptors CXCR3, CXCR1, ACKR3 KMT2A 2185/4885NISCH 4885/4885
US-12037328-B2 Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 GPR119, GPR3, GPR39 KMT2A 3078/4885NISCH 4335/4885
US-20240216346-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same XBP1, ERN1, ERN2 KMT2A 3358/4885NISCH 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.